Payment overview · 2025
General Payments
$3,882.73
187 reported records · 18 companies
Healthcare provider profile · identity verified
Jo S Koepsel, PMHWP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · CORPUS CHRISTI, TX · NPI 1104885086
Verified facts
What the public records show
CMS Open Payments records show Jo S Koepsel, PMHWP received $3,882.73 in general payments during 2025 across 187 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 15.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Fanapt, Ingrezza, Invega Sustenna, Lybalvi, Nuplazid, Quviviq, Rexulti, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Vraylar by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nuplazid by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYBALVI as an associated drug or biological on 93784 records involving 20135 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Lybalvi by this doctor in 2024.
IDORSIA PHARMACEUTICALS US INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QUVIVIQ as an associated drug or biological on 2281 records involving 1911 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Quviviq by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Invega Sustenna by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Rexulti by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Ingrezza by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Rexulti by this doctor in 2024.
Vanda Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FANAPT as an associated drug or biological on 95605 records involving 21383 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Fanapt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $602.93 | 15.5% | 23 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $443.55 | 11.4% | 35 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $411.83 | 10.6% | 26 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $405.08 | 10.4% | 12 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $381.27 | 9.8% | 21 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $279.41 | 7.2% | 14 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $277.36 | 7.1% | 12 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $242.43 | 6.2% | 7 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $173.37 | 4.5% | 4 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $160.73 | 4.1% | 10 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $117.93 | 3.0% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $90.63 | 2.3% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $85.27 | 2.2% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $79.10 | 2.0% | 6 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $45.78 | 1.2% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $44.82 | 1.1% | 2 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $21.87 | 0.6% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $19.37 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,771.24 | 186 |
| Education | $111.49 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $411.83 | 26 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $405.08 | 12 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $381.27 | 21 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $376.75 | 30 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $308.99 | 25 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $279.41 | 14 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $259.50 | 16 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $242.43 | 7 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $241.86 | 11 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $231.94 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $215.16 | 6 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $160.73 | 10 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $117.93 | 2 | 2025 |
Source payment records
|
|||||
| ARISTADA INITIO Normalized: aristada initio |
Drug | Alkermes, Inc. | $102.84 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $79.10 | 6 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $55.73 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $44.82 | 2 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Lundbeck LLC | $43.48 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $34.90 | 2 | 2025 |
Source payment records
|
|||||
| Onyda XR Normalized: onyda xr |
Drug | Tris Pharma Inc | $27.87 | 2 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $19.37 | 1 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $17.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FANAPT fanapt |
2025 | Fanapt | 2024 | 101 | exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INVEGA SUSTENNA invega sustenna |
2025 | Invega Sustenna | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LYBALVI lybalvi |
2025 | Lybalvi | 2024 | 98 | exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Quviviq quviviq |
2025 | Quviviq | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 84 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 84 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
84 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | LYBALVI open payments reported associated product |
CMS Open Payments — General Payments 93784 supporting records · 20135 recipient NPIs · example record 1222428566 |
Lybalvi · 2024 Exact normalized brand match · 1 Part D row |
98 | 12 |
| IDORSIA PHARMACEUTICALS US INC Exact reporting entity; no affiliate inference |
2025 | QUVIVIQ open payments reported associated product |
CMS Open Payments — General Payments 2281 supporting records · 1911 recipient NPIs · example record 1243392023 |
Quviviq · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
84 | 11 |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
84 | 11 |
| Vanda Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | FANAPT open payments reported associated product |
CMS Open Payments — General Payments 95605 supporting records · 21383 recipient NPIs · example record 1232940535 |
Fanapt · 2024 Exact normalized brand match · 1 Part D row |
101 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Trazodone Hcl | Trazodone Hcl | 505 | 63 |
| Divalproex Sodium Er | Divalproex Sodium | 333 | 33 |
| Clonazepam | Clonazepam | 311 | 45 |
| Sertraline Hcl | Sertraline Hcl | 260 | 27 |
| Olanzapine | Olanzapine | 244 | 25 |
| Risperidone | Risperidone | 235 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 218 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 184 | 19 |
| Aptiom | Eslicarbazepine Acetate | 182 | 24 |
| Donepezil Hcl | Donepezil Hcl | 175 | 25 |
| Lorazepam | Lorazepam | 167 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 161 | 16 |
| Naltrexone Hcl | Naltrexone Hcl | 146 | 16 |
| Benztropine Mesylate | Benztropine Mesylate | 143 | 16 |
| Aripiprazole | Aripiprazole | 135 | 18 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 108 | 15 |
| Fanapt | Iloperidone | 101 | 11 |
| Lybalvi | Olanzapine/Samidorphan Malate | 98 | 12 |
| Buspirone Hcl | Buspirone Hcl | 90 | 11 |
| Rexulti | Brexpiprazole | 84 | 11 |
| Vraylar | Cariprazine Hcl | 84 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 77 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 77 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 76 | 13 |
| Divalproex Sodium | Divalproex Sodium | 76 | 11 |
| Alprazolam Er | Alprazolam | 75 | 13 |
| Temazepam | Temazepam | 75 | suppressed |
| Mirtazapine | Mirtazapine | 74 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 69 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 67 | 11 |
| Lurasidone Hcl | Lurasidone Hcl | 65 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 62 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 13 |
| Rivastigmine | Rivastigmine Tartrate | 61 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 59 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 57 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 54 | suppressed |
| Bupropion Xl | Bupropion Hcl | 50 | 11 |
| Gabapentin | Gabapentin | 50 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 50 | suppressed |
| Carbamazepine Er | Carbamazepine | 49 | suppressed |
| Alprazolam | Alprazolam | 43 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 43 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 41 | suppressed |
| Amantadine | Amantadine Hcl | 40 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 39 | suppressed |
| Paliperidone Er | Paliperidone | 39 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Ingrezza | Valbenazine Tosylate | 35 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 35 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 33 | suppressed |
| Lamotrigine | Lamotrigine | 32 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 30 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Zaleplon | Zaleplon | 27 | suppressed |
| Eszopiclone | Eszopiclone | 26 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 25 | suppressed |
| Belsomra | Suvorexant | 25 | suppressed |
| Carbamazepine | Carbamazepine | 25 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 25 | suppressed |
| Quviviq | Daridorexant Hcl | 25 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 24 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 19 | suppressed |
| Alprazolam Xr | Alprazolam | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 15 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 12 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 12 | suppressed |
| Clozapine | Clozapine | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Omeprazole | Omeprazole | 12 | suppressed |
| Perseris | Risperidone | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Ramelteon | Ramelteon | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 11 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,882.73 · 187 records | Teva Pharmaceuticals USA, Inc. | ABILIFY ASIMTUFII, ARISTADA, ARISTADA INITIO, AUSTEDO XR, Auvelity, Azstarys, CAPLYTA, COBENFY, Dyanavel XR, FANAPT, INGREZZA, INVEGA SUSTENNA, Jornay PM, LYBALVI, NUPLAZID, Onyda XR, Qelbree, Quviviq, REXULTI, SPRAVATO, SUBLOCADE, UZEDY, VRAYLAR | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Fanapt play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error